PAI-1 inhibition shows preclinical promise; elevated levels linked to poor cancer prognosis

A systematic review examined the role of plasminogen activator inhibitor-1 (PAI-1) in cancer biology and its potential as a therapeutic target. The review covered malignancies including breast, ovarian, lung, hepatobiliary, colorectal, and glioblastoma, though specific population details, sample size, and study settings were not reported. The analysis focused on PAI-1 inhibition strategies, including small-molecule inhibitors and monoclonal antibodies, with no specific comparator detailed.

The main findings revealed two key observations. First, elevated levels of PAI-1 were consistently associated with poor prognosis across several malignancies, though no specific effect sizes, absolute numbers, or statistical measures were reported. Second, strategies to inhibit PAI-1 demonstrated promise in preclinical research, indicating potential therapeutic avenues.

No safety, tolerability, or adverse event data were reported in this review. Key limitations stem from the nature of the evidence: the therapeutic findings are exclusively from preclinical research, and the prognostic findings represent associations rather than established causation. The review did not report funding sources or conflicts of interest.

For clinical practice, this review highlights PAI-1 as a biologically relevant marker and potential target in oncology. However, the evidence remains preliminary. The prognostic association suggests PAI-1 may have utility as a biomarker, but clinical validation is needed. The therapeutic promise of PAI-1 inhibitors requires confirmation through clinical trials before any treatment implications can be drawn.